EPOCH 32: BIOTECH MARKET RESEARCH ($IMVT)

Immunovant, Inc.

This week we are featuring Immunovant.  The company has an upcoming Ph1 readout for their Neonatal Fc Receptor program also named IMVT-1402.  There is strong evidence of IgG Reduction being efficacious across various auto-immune indications via reduction of auto-antibodies.  The single ascending dose (SAD) will be shared late-August / September and depending on the therapeutic index we will get an early read on the best-in-class potential for this therapeutic.  Options pricing projects a 20-30% move, so there should be volatility to play.

As a reminder, every Monday we are out with public biotech research, profiling biotech companies with near term catalysts. This will focus primarily on the major market moving biotech events such as data readouts from the major scientific conferences as well as potential regulatory approvals.

We will not offer specific trading advice (and we do not hold any publicly traded biotech equity), but rather flag emerging events that will likely materially drive stock prices (sometimes +/-100% in either direction).

Be sure to SUBSCRIBE to not miss.

HOW TO PLAY BIOTECH APPROVAL/DATA READOUTS ANNOUNCEMENTS

While biotech equities will move on news of announcement, often if there is high conviction in a positive read, a large run up ahead of the news will occur and the actual event turns into a sell the news event. Sometimes, investors wait for the actual event to make a long/short decision. And obviously if the news is disappointing (more often than not) the stock will tank.

This is not financial advice so you will have to make your own call on how to best play these events.

ALERT: Immunovant ($IMVT)  Ph1 data readout MVT-1402 for IgG Reduction in auto-immune

DATE: Aug/Sep

IMPLIED VOLATILITY: +/- 20-30%

BACKGROUND: 

From the company website: